Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
Keywords: Uterine serous tumors; HER2/neu; PIK3CA mutation; GDC-0032; Taselisib; PIK3CA-mutant mouse;